Compare IRON & SHOO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | SHOO |
|---|---|---|
| Founded | 2017 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2020 | 1996 |
| Metric | IRON | SHOO |
|---|---|---|
| Price | $70.47 | $38.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $103.18 | $42.43 |
| AVG Volume (30 Days) | 356.5K | ★ 955.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.23% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.63 |
| Revenue | N/A | ★ $2,534,109,000.00 |
| Revenue This Year | N/A | $12.39 |
| Revenue Next Year | $283.52 | $5.90 |
| P/E Ratio | ★ N/A | $59.72 |
| Revenue Growth | N/A | ★ 11.00 |
| 52 Week Low | $39.20 | $19.06 |
| 52 Week High | $99.50 | $46.88 |
| Indicator | IRON | SHOO |
|---|---|---|
| Relative Strength Index (RSI) | 64.19 | 64.77 |
| Support Level | $57.79 | $31.85 |
| Resistance Level | $82.70 | $40.18 |
| Average True Range (ATR) | 2.83 | 1.17 |
| MACD | 1.07 | 0.73 |
| Stochastic Oscillator | 96.17 | 99.09 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Steven Madden Ltd and its subsidiaries design, source, and market branded and private label footwear, accessories, and apparel. Its offerings include contemporary styles and core products, known for design creativity, trend-right offerings, high quality, and accessible price points. It operates through four segments: Wholesale Footwear, which generates maximum revenue and sells footwear globally; Wholesale Accessories/Apparel, which sells handbags and apparel through wholesale channels; Direct-to-Consumer, which sells footwear, handbags, apparel, and accessories through stores, outlets, e-commerce, and concessions; and Licensing, which licenses Steve Madden, Betsey Johnson, and Kurt Geiger trademarks, with the Company generating the majority of its revenue from the USA.